Arbutus Biopharma Corporation
NASDAQ:ABUSBiotechnology
+$0.05 today
- Market cap
- $630.03M
- Beta
- 0.63
- P/E (TTM)
- 5.4
- EPS (TTM)
- $0.83
Volume 2.90M
Average 1.76M
ABUS Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Arbutus Biopharma CorporationNASDAQ: ABUS
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income turns positive
Q1 FY2026 net income was $169.7M, compared with -$24.53M a year earlier. Trailing-twelve-month net income was $160.72M. Over 3 fiscal years it compounded at -21.6% a year.
Context
- Net income amounted to 237.9% of revenue in FY2025, down 895.2 pp from a year earlier.
- Net income grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 1 analysts of $141.78M (+523.2%) for the fiscal year ending Dec 2026, a step up from the -52.1% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $169.7M+4618.0% QoQ
- Last fiscal yearDec 2025
- -$33.5M-52.1% YoY
- LTMMar 2026
- $160.72M+309.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +791.9% | -258.2% | -1050.1 pp |
| 1 year | -52.1% | +523.2% | +575.3 pp |
| 3-year CAGR | -21.6% | -7.1% | +14.4 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (33.5M) USD
- Year-over-year change
- +52.1%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (33.5M) | +52.1% |
| FY2024 | 2024-12-31 | (69.92M) | +4.0% |
| FY2023 | 2023-12-31 | (72.85M) | -4.9% |
| FY2022 | 2022-12-31 | (69.46M) | +8.9% |
| FY2021 | 2021-12-31 | (76.25M) | — |
Net Income vs competitors
How ABUS compares with its peers on the latest reported figures
- ABUS's LTM Mar 2026 net income of $160.72M is the 5th largest of the 9 companies compared; the peer median is $103.71M.
- Its year-over-year change of +309.9% is the 2nd highest of 8, against a peer median of -23.4%.
- Net income amounts to 84.0% of revenue for ABUS, versus a peer median of 124.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $807.99M | +353.2% | — | 16.8% | |
| LTM Sep 2026 | $717.13M | -2481.4% | +50.8% | 159.1% | |
| LTM Mar 2026 | $442.72M | -23.4% | — | 676.0% | |
| LTM Mar 2026 | $169.52M | +21.5% | +11.0% | — | |
| LTM Mar 2026 | $160.72M | +309.9% | -21.6% | 84.0% | |
| LTM Mar 2026 | $145.44M | — | +20.7% | 15782.6% | |
| LTM Mar 2026 | $61.98M | -35.7% | -12.4% | 89.6% | |
| LTM Mar 2026 | $41.54M | +56.8% | +27.7% | — | |
| LTM Mar 2026 | $6.38M | -84.0% | -59.6% | 9.0% | |
| Peer median (excluding ABUS) | $103.71M | -23.4% | +15.9% | 124.3% | |
Competitors are the stored peer set for ABUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (76.25M) | (69.46M) | (72.85M) | (69.92M) | (33.5M) |
| Depreciation & Amortization | 1.75M | 1.43M | 1.4M | 1.38M | 363K |
| Deferred Income Tax | (8.18M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.42M | 7.18M | 9.3M | 8.99M | 6.95M |
| Change in Working Capital | 930K | 29.24M | (18.23M) | (2.83M) | (10.02M) |
| Accounts Receivables | 413K | (453K) | (424K) | (633K) | 1.38M |
| Inventory | (1.91M) | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.91M | 5.22M | 0 | 0 | (2.11M) |
| Other Working Capital | 517K | 24.48M | (17.81M) | (2.2M) | (9.29M) |
| Other Non-Cash Items | 7.79M | (3.75M) | (5.56M) | (2.47M) | (3.43M) |
| Operating Cash Flow | (67.53M) | (35.36M) | (85.94M) | (64.85M) | (39.64M) |
| Capital Expenditures | (809K) | (512K) | (1.01M) | (182K) | 0 |
| Acquisitions (Net) | 1.81M | 0 | 0 | 0 | 0 |
| Purchases of Investments | (82.22M) | (130.43M) | (80.51M) | (141.51M) | 12.87M |
| Sales of Investments | 70.35M | 56M | 132.27M | 164.64M | 155.28M |
| Other Investing Activities | (1.81M) | 0 | 20K | 0 | (152.56M) |
| Investing Cash Flow | (12.68M) | (74.94M) | 50.77M | 22.95M | 15.58M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 134.67M | 20.32M | 29.85M | 44.12M | 5.72M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (12.14M) | 0 | 0 | 0 | 0 |
| Other Financing Activities | 14.71M | 11.49M | 795K | 7.87M | 0 |
| Financing Cash Flow | 137.24M | 31.81M | 30.65M | 52M | 5.72M |
| Effect of Forex Changes | 5K | (22K) | 25K | (49K) | 14K |
| Net Change in Cash | 57.03M | (78.51M) | (4.49M) | 10.05M | (18.32M) |
| Free Cash Flow | (68.34M) | (35.87M) | (86.94M) | (65.03M) | (39.64M) |
Arbutus Biopharma Corporation
NASDAQ:ABUS
Intrinsic Alpha fair value
Locked
Current Price
$4.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.